Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding

@article{Feinmann2021Covid19GV,
  title={Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding},
  author={Jane Feinmann},
  journal={BMJ},
  year={2021},
  volume={375}
}
Vaccination efforts around the world are being restrained by a shortage of doses. Jane Feinmann looks at what is holding up the process 

Optimal Vaccine Allocation: Modelling Population Interaction and Administrative Constraints

The COVID-19 pandemic and associated vaccine shortages in many places have caused immense suffering. This paper proposes a theoretical framework for finding the optimal vaccine allocation among

The role of childrens’ vaccination for COVID-19—Pareto-optimal allocations of vaccines

It is found that in a broad range of scenarios, optimal allocations of vaccines do not include vaccination of age-group 0-9, and when some weight is given to the number of infections, it is optimal to allocate vaccines to adolescents in the age group 10-19.

Addressing vaccine hesitancy and resistance for COVID-19 vaccines

  • M. Peters
  • Medicine, Political Science
    International Journal of Nursing Studies
  • 2022

Global COVID-19 vaccine inequity: Preferences for overseas vaccine donations over booster shots

Latin America in the fight against the Coronavirus crisis: The impact on economic and political stability in the region

The world has entered the third decade of the century, gripped by the global crisis and the COVID-19. These specific conditions have undermined the development and sustainability of the less prepared

Memo to COP26 leaders: abandon your hubris, politics, and pride and see the future through young people’s eyes

Many places in the world with the highest PM2.5 levels are also urban areas vulnerable to the health risks of extreme heat; and regions of high particulate air pollution and extreme heat are also affected by vaccine injustice.

In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment

It is suggested that niclosamide is not an ideal candidate for the treatment of COVID-19, but that there is potential for developing improved analogs with higher clinical translational potential in the future.

In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment

It is shown that niclosamide is not a suitable candidate for the treatment of COVID-19, but that structural analogs with improved drug properties may have higher clinical-translational potential in the future.

General vaccination knowledge influences nurses’ and midwives’ COVID-19 vaccination intention in Cyprus: a nationwide cross-sectional study

It is demonstrated that COVID-19 vaccination acceptance is related to the vaccination knowledge of the nurses and midwives in Cyprus and targeted vaccination campaigns are needed to improve nurses’ and midwife’ level of vaccination knowledge.

Subgenomic SARS-CoV-2 replicon and reporter replicon cell lines enable ultrahigh throughput antiviral screening and mechanistic studies with antivirals, viral mutations or host factors that affect COVID-19 replication

Replicon-based reagents include a novel approach to replicon-harboring cell line generation and are valuable tools that can be used at lower biosafety level (BSL2) for drug discovery efforts, characterization of Sars-CoV-2 and variant evolution in the COVID-19 pandemic, mechanisms of inhibition and resistance, and studies on the role of SARS-Cov-2 genes and host dependency factors.

References

SHOWING 1-2 OF 2 REFERENCES

Jeremy Farrar: Make vaccine available to other countries as soon as our most vulnerable people have received it

The SAGE adviser and Wellcome Trust director tells Mun-Keat Looi how the UK government acted too slowly against the pandemic, about the perils of vaccine nationalism, and why he is bullish about